Join to access to all OVN content. Join for Free
Filler Words Fix the Problem You Didn't Know You Had
filler words communication skills professional presence audience engagement verbal fillers

Filler Words Fix the Problem You Didn't Know You Had


Share This Article


Summary

In this episode, Tom Caravela delves into the significance of eliminating filler words in professional as well as personal communication. He highlights the impact of these verbal fillers on perceived competence and interview performance, supported by revealing statistics. Tom explores the demographic differences in the use of filler words and their effects on audience engagement. He provides practical strategies for reducing filler words, emphasizing the importance of preparation, practice, and the power of slowing down and pausing. The episode concludes with insights on mindfulness and self-awareness in speech, encouraging listeners to refine their communication skills for enhanced professional presence.

Key Points

  • Eliminating filler words can significantly enhance your professional image, making you appear more confident and competent.
  • Preparation and practice are key to eliminating the need to fill gaps with habitual words.
  • Slowing down and embracing pauses in your speech can improve clarity and engagement, preventing the need for filler words.

Click for Source
filler words, communication skills, professional presence, audience engagement, verbal fillers

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Be Brave-A Networking Tale that Led to Friendship
Partner Avatar MSL Talk, Tom Caravela, Josh Yoder, Kirsten Borbe

Be Brave-A Networking Tale that Led to Friendship

Podcast
Top 5 MSL Frustrations and How to Overcome Them
Partner Avatar MSL Talk: Tom Caravela

Top 5 MSL Frustrations and How to Overcome Them

Article
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
OVN Avatar S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny

Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale

Article
Sponsorship of oncology clinical trials in the United States according to age of eligibility
OVN Avatar Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois

Sponsorship of oncology clinical trials in the United States according to age of eligibility

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Article
Finding the Right Drug at the Right Dose the First Time: Has the Era of Personalized Formularies Finally Arrived?
OVN Avatar Karen Geary

Finding the Right Drug at the Right Dose the First Time: Has the Era of Personalized Formularies Finally Arrived?

Explore OVN